Defense Department backs new study of Idorsia's Quviviq as a treatment for PTSD

Of a variety of medications for post-traumatic stress disorder (PTSD), antidepressants are the most commonly used. For many with PTSD, however, these and other treatments aren’t sufficient.

But a new answer may be on its way. A study sponsored by the Department of Defense (DOD) will test the effectiveness of Idorsia’s newly approved insomnia drug Quviviq in those with PTSD.